Dermata Therapeutics, Inc. (DRMA)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Mar 12, 2025

$1.22

P/E Ratio

N/A

Market Cap

$6.32M

Mar 20, 2024Apr 24, 2024May 29, 2024Jul 2, 2024Aug 2, 2024Sep 5, 2024Oct 8, 2024Nov 11, 2024Dec 17, 2024Jan 24, 2025Mar 12, 2025$0.00$10.00
  • DRMA
Description
Add to research

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.

Metrics
Add to research

Overview

  • HQSan Diego, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerDRMA
  • Price$1.22-0.81%

Trading Information

  • Market cap$6.32M
  • Float73.47%
  • Average Daily Volume (1m)192,293
  • Average Daily Volume (3m)381,538
  • EPS-$21.42

Company

  • RevenueN/A
  • Rev growth (1yr)N/A
  • Net income-$3.17M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$3.23M
  • EV-$3.59M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B0.43
  • Debt/EquityN/A
Documents
Add to research